- Home
- Publications
- Publication Search
- Publication Details
Title
Towards precision medicine for AML
Authors
Keywords
-
Journal
Nature Reviews Clinical Oncology
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2021-05-18
DOI
10.1038/s41571-021-00509-w
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Eprenetapopt (APR-246) and Azacitidine in TP53-Mutant Myelodysplastic Syndromes
- (2021) David A. Sallman et al. JOURNAL OF CLINICAL ONCOLOGY
- Clonal evolution of acute myeloid leukemia with FLT3-ITD mutation under treatment with midostaurin
- (2021) Laura Katharina Schmalbrock et al. BLOOD
- Eprenetapopt Plus Azacitidine in TP53-Mutated Myelodysplastic Syndromes and Acute Myeloid Leukemia: A Phase II Study by the Groupe Francophone des Myélodysplasies (GFM)
- (2021) Thomas Cluzeau et al. JOURNAL OF CLINICAL ONCOLOGY
- The First-in-Class Anti-CD47 Antibody Magrolimab (5F9) in Combination with Azacitidine Is Effective in MDS and AML Patients: Ongoing Phase 1b Results
- (2020) David A Sallman et al. BLOOD
- Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML
- (2020) Courtney D. DiNardo et al. BLOOD
- Enasidenib Plus Azacitidine Significantly Improves Complete Remission and Overall Response Compared with Azacitidine Alone in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) with Isocitrate Dehydrogenase 2 (IDH2) Mutations: Interim Phase II Results from an Ongoing, Randomized Study
- (2020) Courtney D. DiNardo et al. BLOOD
- Therapeutic targeting of preleukemia cells in a mouse model of NPM1 mutant acute myeloid leukemia
- (2020) Hannah J. Uckelmann et al. SCIENCE
- Monocytic Subclones Confer Resistance to Venetoclax-Based Therapy in Acute Myeloid Leukemia Patients
- (2020) Shanshan Pei et al. Cancer Discovery
- Therapeutic Targeting of the Macrophage Immune Checkpoint CD47 in Myeloid Malignancies
- (2020) Mark P. Chao et al. Frontiers in Oncology
- Oral cedazuridine/decitabine: a phase 2, pharmacokinetic/pharmacodynamic, randomized, crossover study in MDS and CMML
- (2020) Guillermo Garcia-Manero et al. BLOOD
- Venetoclax plus LDAC for patients with untreated AML ineligible for intensive chemotherapy: phase 3 randomized placebo-controlled trial
- (2020) Andrew Henry Wei et al. BLOOD
- Updated results from phase I dose-escalation study of AMG 330, a bispecific T-cell engager molecule, in patients with relapsed/refractory acute myeloid leukemia (R/R AML).
- (2020) Farhad Ravandi et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase Ib/II study of the IDH1-mutant inhibitor ivosidenib with the BCL2 inhibitor venetoclax +/- azacitidine in IDH1-mutated hematologic malignancies.
- (2020) Curtis Andrew Lachowiez et al. JOURNAL OF CLINICAL ONCOLOGY
- Rapidly Switchable Universal CAR-T cells for Treatment of CD123-positive Leukemia
- (2020) Simon Loff et al. Molecular Therapy-Oncolytics
- Chemotherapy and Venetoclax in Elderly Acute Myeloid Leukemia Trial (CAVEAT): A Phase Ib Dose-Escalation Study of Venetoclax Combined With Modified Intensive Chemotherapy
- (2020) Chong Chyn Chua et al. JOURNAL OF CLINICAL ONCOLOGY
- Sorafenib Maintenance After Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia With FLT3–Internal Tandem Duplication Mutation (SORMAIN)
- (2020) Andreas Burchert et al. JOURNAL OF CLINICAL ONCOLOGY
- Sorafenib maintenance in patients with FLT3-ITD acute myeloid leukaemia undergoing allogeneic haematopoietic stem-cell transplantation: an open-label, multicentre, randomised phase 3 trial
- (2020) Li Xuan et al. LANCET ONCOLOGY
- Targeting CD70 with cusatuzumab eliminates acute myeloid leukemia stem cells in patients treated with hypomethylating agents
- (2020) Carsten Riether et al. NATURE MEDICINE
- Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia
- (2020) Courtney D. DiNardo et al. NEW ENGLAND JOURNAL OF MEDICINE
- Immune landscapes predict chemotherapy resistance and immunotherapy response in acute myeloid leukemia
- (2020) Jayakumar Vadakekolathu et al. Science Translational Medicine
- Chromatin Complexes Maintain Self-Renewal of Myeloid Progenitors in AML: Opportunities for Therapeutic Intervention
- (2020) Hannah J. Uckelmann et al. Stem Cell Reports
- Molecular mechanisms mediating relapse following ivosidenib monotherapy in IDH1-mutant relapsed or refractory AML
- (2020) Sung Choe et al. Blood Advances
- Flotetuzumab as Salvage Immunotherapy for Refractory Acute Myeloid Leukemia
- (2020) Geoffrey L Uy et al. BLOOD
- Impact of gemtuzumab ozogamicin on MRD and relapse risk in NPM1 mutated AML patients: results from the AMLSG 09-09 Trial
- (2020) Silke Kapp-Schwoerer et al. BLOOD
- Ivosidenib or enasidenib combined with intensive chemotherapy in patients with newly diagnosed AML: a phase 1 study
- (2020) Eytan M. Stein et al. BLOOD
- Entospletinib in Combination with Induction Chemotherapy in Previously Untreated Acute Myeloid Leukemia: Response and Predictive Significance of HOXA9 and MEIS1 Expression
- (2020) Alison R. Walker et al. CLINICAL CANCER RESEARCH
- Precision medicine treatment in acute myeloid leukemia using prospective genomic profiling: feasibility and preliminary efficacy of the Beat AML Master Trial
- (2020) Amy Burd et al. NATURE MEDICINE
- Clonal evolution of acute myeloid leukemia revealed by high-throughput single-cell genomics
- (2020) Kiyomi Morita et al. Nature Communications
- Midostaurin in patients with acute myeloid leukemia and FLT3-TKD mutations: a subanalysis from the RATIFY trial
- (2020) Maria Teresa Voso et al. Blood Advances
- Randomized trials with checkpoint inhibitors in acute myeloid leukaemia and myelodysplastic syndromes: What have we learned so far and where are we heading?
- (2020) Jan Philipp Bewersdorf et al. BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY
- Mutant Isocitrate Dehydrogenase 1 Inhibitor Ivosidenib in Combination With Azacitidine for Newly Diagnosed Acute Myeloid Leukemia
- (2020) Courtney D. DiNardo et al. JOURNAL OF CLINICAL ONCOLOGY
- Oral Azacitidine Maintenance Therapy for Acute Myeloid Leukemia in First Remission
- (2020) Andrew H. Wei et al. NEW ENGLAND JOURNAL OF MEDICINE
- Clinical resistance to crenolanib in acute myeloid leukemia due to diverse molecular mechanisms
- (2019) Haijiao Zhang et al. Nature Communications
- Venetoclax Combined With Low-Dose Cytarabine for Previously Untreated Patients With Acute Myeloid Leukemia: Results From a Phase Ib/II Study
- (2019) Andrew H. Wei et al. JOURNAL OF CLINICAL ONCOLOGY
- Concomitant targeting of BCL2 with venetoclax and MAPK signaling with cobimetinib in acute myeloid leukemia models
- (2019) Lina Han et al. HAEMATOLOGICA
- Enasidenib, an inhibitor of mutant IDH2 proteins, induces durable remissions in older patients with newly diagnosed acute myeloid leukemia
- (2019) Daniel A. Pollyea et al. LEUKEMIA
- Clonal selection with Ras pathway activation mediates secondary clinical resistance to selective FLT3 inhibition in acute myeloid leukemia
- (2019) Christine M. McMahon et al. Cancer Discovery
- Targeting mitochondrial structure sensitizes acute myeloid leukemia to Venetoclax treatment
- (2019) Xufeng Chen et al. Cancer Discovery
- The TP53 Apoptotic Network is a Primary Mediator of Resistance to BCL2 inhibition in AML Cells
- (2019) Tamilla Nechiporuk et al. Cancer Discovery
- Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial
- (2019) Jorge E Cortes et al. LANCET ONCOLOGY
- A dominant-negative effect drives selection of TP53 missense mutations in myeloid malignancies
- (2019) Steffen Boettcher et al. SCIENCE
- Phase 1 Dose Escalation and Expansion Study to Determine Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the BET Inhibitor FT-1101 As a Single Agent in Patients with Relapsed or Refractory Hematologic Malignancies
- (2019) Manish R. Patel et al. BLOOD
- Venetoclax in Combination with Gilteritinib in Patients with Relapsed/Refractory Acute Myeloid Leukemia: A Phase 1b Study
- (2019) Alexander E. Perl et al. BLOOD
- Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML
- (2019) Alexander E. Perl et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1-mutant acute myeloid leukemia
- (2019) Gail J. Roboz et al. BLOOD
- Mutational profile and benefit of gemtuzumab ozogamicin in acute myeloid leukemia
- (2019) Elise Fournier et al. BLOOD
- A Menin-MLL Inhibitor Induces Specific Chromatin Changes and Eradicates Disease in Models of MLL-Rearranged Leukemia
- (2019) Andrei V. Krivtsov et al. CANCER CELL
- Menin inhibitor MI-3454 induces remission in MLL1-rearranged and NPM1-mutated models of leukemia
- (2019) Szymon Klossowski et al. JOURNAL OF CLINICAL INVESTIGATION
- The growing landscape of FLT3 inhibition in AML
- (2019) Catherine C. Smith Hematology-American Society of Hematology Education Program
- Genetic Biomarkers Of Sensitivity and Resistance to Venetoclax Monotherapy in Patients With Relapsed Acute Myeloid Leukemia
- (2018) Brenda Chyla et al. AMERICAN JOURNAL OF HEMATOLOGY
- The DOT1L inhibitor pinometostat reduces H3K79 methylation and has modest clinical activity in adult acute leukemia
- (2018) Eytan M. Stein et al. BLOOD
- Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party
- (2018) Gerrit J. Schuurhuis et al. BLOOD
- Tyrosine kinase inhibitor–induced defects in DNA repair sensitize FLT3(ITD)-positive leukemia cells to PARP1 inhibitors
- (2018) Silvia Maifrede et al. BLOOD
- Genetic Inactivation of CD33 in Hematopoietic Stem Cells to Enable CAR T Cell Immunotherapy for Acute Myeloid Leukemia
- (2018) Miriam Y. Kim et al. CELL
- IDH1/2Mutations Sensitize Acute Myeloid Leukemia to PARP Inhibition and This Is Reversed by IDH1/2-Mutant Inhibitors
- (2018) Remco J. Molenaar et al. CLINICAL CANCER RESEARCH
- Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trial
- (2018) Jorge Cortes et al. LANCET ONCOLOGY
- Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study
- (2018) Courtney D DiNardo et al. LANCET ONCOLOGY
- Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells
- (2018) Nimitha R Mathew et al. NATURE MEDICINE
- Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML
- (2018) Courtney D. DiNardo et al. NEW ENGLAND JOURNAL OF MEDICINE
- APR-246 reactivates mutant p53 by targeting cysteines 124 and 277
- (2018) Qiang Zhang et al. Cell Death & Disease
- Differentiation Syndrome Associated With Enasidenib, a Selective Inhibitor of Mutant Isocitrate Dehydrogenase 2
- (2018) Amir T. Fathi et al. JAMA Oncology
- Gemtuzumab ozogamicin for de novo acute myeloid leukemia: final efficacy and safety updates from the open-label, phase 3 ALFA-0701 trial
- (2018) Juliette Lambert et al. HAEMATOLOGICA
- Combining BH3-mimetics to target both BCL-2 and MCL1 has potent activity in pre-clinical models of acute myeloid leukemia
- (2018) Donia M. Moujalled et al. LEUKEMIA
- Acquired resistance to IDH inhibition through trans or cis dimer-interface mutations
- (2018) Andrew M. Intlekofer et al. NATURE
- Molecular remission and response patterns in patients with mutant-IDH2 acute myeloid leukemia treated with enasidenib
- (2018) Eytan M. Stein et al. BLOOD
- Midostaurin added to chemotherapy and continued single agent maintenance therapy in acute myeloid leukemia with FLT3-ITD
- (2018) Richard F. Schlenk et al. BLOOD
- Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia
- (2018) Courtney D. DiNardo et al. BLOOD
- Inhibition of Amino Acid Metabolism Selectively Targets Human Leukemia Stem Cells
- (2018) Courtney L. Jones et al. CANCER CELL
- Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome
- (2018) Jorge E. Cortes et al. LEUKEMIA
- Cytogenetics and gene mutations influence survival in older patients with acute myeloid leukemia treated with azacitidine or conventional care
- (2018) Hartmut Döhner et al. LEUKEMIA
- Venetoclax with azacitidine disrupts energy metabolism and targets leukemia stem cells in patients with acute myeloid leukemia
- (2018) Daniel A. Pollyea et al. NATURE MEDICINE
- Discovery of Mcl-1-specific inhibitor AZD5991 and preclinical activity in multiple myeloma and acute myeloid leukemia
- (2018) Adriana E. Tron et al. Nature Communications
- Isoform Switching as a Mechanism of Acquired Resistance to Mutant Isocitrate Dehydrogenase Inhibition
- (2018) James J. Harding et al. Cancer Discovery
- Genomics of Acute Myeloid Leukemia Diagnosis and Pathways
- (2017) Lars Bullinger et al. JOURNAL OF CLINICAL ONCOLOGY
- Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1–2 study
- (2017) Alexander E Perl et al. LANCET ONCOLOGY
- Enhancing venetoclax activity in acute myeloid leukemia by co-targeting MCL1
- (2017) T-C Teh et al. LEUKEMIA
- A phase 1b/2b multicenter study of oral panobinostat plus azacitidine in adults with MDS, CMML or AML with ⩽30% blasts
- (2017) G Garcia-Manero et al. LEUKEMIA
- Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation
- (2017) Richard M. Stone et al. NEW ENGLAND JOURNAL OF MEDICINE
- AG-221, a First-in-Class Therapy Targeting Acute Myeloid Leukemia Harboring Oncogenic IDH2 Mutations
- (2017) Katharine Yen et al. Cancer Discovery
- Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
- (2016) Hartmut Döhner et al. BLOOD
- The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia
- (2016) D. A. Arber et al. BLOOD
- Small-molecule Hedgehog inhibitor attenuates the leukemia-initiation potential of acute myeloid leukemia cells
- (2016) Nobuaki Fukushima et al. CANCER SCIENCE
- CD70/CD27 signaling promotes blast stemness and is a viable therapeutic target in acute myeloid leukemia
- (2016) Carsten Riether et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Genomic Classification and Prognosis in Acute Myeloid Leukemia
- (2016) Elli Papaemmanuil et al. NEW ENGLAND JOURNAL OF MEDICINE
- Switching CAR T cells on and off: a novel modular platform for retargeting of T cells to AML blasts
- (2016) M Cartellieri et al. Blood Cancer Journal
- Targeting Chromatin Regulators Inhibits Leukemogenic Gene Expression in NPM1 Mutant Leukemia
- (2016) M. W. M. Ku hn et al. Cancer Discovery
- Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia
- (2016) M. Konopleva et al. Cancer Discovery
- International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts
- (2015) H. Dombret et al. BLOOD
- Pharmacologic Inhibition of the Menin-MLL Interaction Blocks Progression of MLL Leukemia In Vivo
- (2015) Dmitry Borkin et al. CANCER CELL
- Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia
- (2015) Steven M Chan et al. NATURE MEDICINE
- Acute Myeloid Leukemia
- (2015) Hartmut Döhner et al. NEW ENGLAND JOURNAL OF MEDICINE
- CD44v6-targeted T cells mediate potent antitumor effects against acute myeloid leukemia and multiple myeloma
- (2013) M. Casucci et al. BLOOD
- Deletion of MCL-1 causes lethal cardiac failure and mitochondrial dysfunction
- (2013) X. Wang et al. GENES & DEVELOPMENT
- Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia
- (2013) NEW ENGLAND JOURNAL OF MEDICINE
- Targeting hedgehog in hematologic malignancy
- (2012) D. A. Irvine et al. BLOOD
- Relative Mitochondrial Priming of Myeloblasts and Normal HSCs Determines Chemotherapeutic Success in AML
- (2012) Thanh-Trang Vo et al. CELL
- Anti-apoptotic Mcl-1 is essential for the development and sustained growth of acute myeloid leukemia
- (2012) S. P. Glaser et al. GENES & DEVELOPMENT
- Targeting p53 in Vivo: A First-in-Human Study With p53-Targeting Compound APR-246 in Refractory Hematologic Malignancies and Prostate Cancer
- (2012) Sören Lehmann et al. JOURNAL OF CLINICAL ONCOLOGY
- Multicenter, Randomized, Open-Label, Phase III Trial of Decitabine Versus Patient Choice, With Physician Advice, of Either Supportive Care or Low-Dose Cytarabine for the Treatment of Older Patients With Newly Diagnosed Acute Myeloid Leukemia
- (2012) Hagop M. Kantarjian et al. JOURNAL OF CLINICAL ONCOLOGY
- Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study
- (2012) Sylvie Castaigne et al. LANCET
- IDH mutation impairs histone demethylation and results in a block to cell differentiation
- (2012) Chao Lu et al. NATURE
- Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia
- (2012) Catherine C. Smith et al. NATURE
- TP53 alterations in acute myeloid leukemia with complex karyotype correlate with specific copy number alterations, monosomal karyotype, and dismal outcome
- (2011) F. G. Rucker et al. BLOOD
- Prospective separation of normal and leukemic stem cells based on differential expression of TIM3, a human acute myeloid leukemia stem cell marker
- (2011) M. Jan et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- The Common Feature of Leukemia-Associated IDH1 and IDH2 Mutations Is a Neomorphic Enzyme Activity Converting α-Ketoglutarate to 2-Hydroxyglutarate
- (2010) Patrick S. Ward et al. CANCER CELL
- Leukemic IDH1 and IDH2 Mutations Result in a Hypermethylation Phenotype, Disrupt TET2 Function, and Impair Hematopoietic Differentiation
- (2010) Maria E. Figueroa et al. CANCER CELL
- DNA Methylation Signatures Identify Biologically Distinct Subtypes in Acute Myeloid Leukemia
- (2010) Maria E. Figueroa et al. CANCER CELL
- TIM-3 Is a Promising Target to Selectively Kill Acute Myeloid Leukemia Stem Cells
- (2010) Yoshikane Kikushige et al. Cell Stem Cell
- CD47 Is Upregulated on Circulating Hematopoietic Stem Cells and Leukemia Cells to Avoid Phagocytosis
- (2009) Siddhartha Jaiswal et al. CELL
- CD47 Is an Adverse Prognostic Factor and Therapeutic Antibody Target on Human Acute Myeloid Leukemia Stem Cells
- (2009) Ravindra Majeti et al. CELL
- Targeting C-type lectin-like molecule-1 for antibody-mediated immunotherapy in acute myeloid leukemia
- (2009) X. Zhao et al. HAEMATOLOGICA
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started